The report analyzes and forecasts the Short bowel syndrome market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of Short bowel syndrome, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Short bowel syndrome companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Short bowel syndrome upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of Short bowel syndrome and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Short bowel syndrome market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Short bowel syndrome market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Short bowel syndrome market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Key Players Mentioned in this Report are:
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the short bowel syndrome market report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S, among others.
The Short Bowel Syndrome Market has been segmented as follows:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Short Bowel Syndrome
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2017–2026
4.3.3. Market Revenue Projections (US$ Mn)
4.4. Porter’s Five Force Analysis
4.5. Value Chain Analysis
4.6. Market Outlook
4.7. Disease Overview
4.8. Disease Epidemiology
4.9. Patent Information
4.10. Overview of Clinical Trials
4.11. Qualitative Analysis of GLP-2 product
4.12. Mode of action of SBS drugs
4.13. Regulatory Scenario
5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
5.4.1. GLP-2
5.4.2. Growth Hormone
5.4.3. Glutamine
5.4.4. Others
5.5. Market Attractiveness by Drug Class
6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
6.1. Key Findings
6.2. Market Value (US$ Mn) Forecast By Region
6.2.1. North America
6.2.2. Europe
6.2.3. Rest of the World
6.3. Market Attractiveness by Country/Region
7. North America Short Bowel Syndrome Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Key Trends
7.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
7.2.1. GLP-2
7.2.2. Growth Hormone
7.2.3. Glutamine
7.2.4. Others
7.3. Market Value (US$ Mn) Forecast By Country, 2017–2026
7.3.1. U.S.
7.3.2. Canada
7.3. Market Attractiveness Analysis
7.3.1. By Drug Class
7.3.2. By Country
8. Europe Short Bowel Syndrome Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Key Trends
8.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
8.2.1. GLP-2
8.2.2. Growth Hormone
8.2.3. Glutamine
8.2.4. Others
8.3. Market Value (US$ Mn) Forecast By Country, 2017–2026
8.3.1. U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Drug Class
8.4.2. By Country
9. Rest of the World Short Bowel Syndrome Analysis and Forecast
9.1. Introduction
9.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
9.3. Regional Insights
9.3.1. Japan
9.3.2. India
9.3.3. Australia/New Zealand
9.3.4. China
9.3.5. Middle East
9.3.6. Brazil
10. Competition Landscape
10.1. Market Player – Competition Matrix (By Tier and Size of companies)
10.2. Market Share Analysis by Company (2015)
10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
10.3.1. Ardelyx, Inc.
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Business Overview
10.3.1.3. Product Portfolio
10.3.1.4. Financial Overview
10.3.1.5. SWOT Analysis
10.3.1.6. Strategic overview
10.3.2. Emmaus Life Sciences, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Business Overview
10.3.2.3. Product Portfolio
10.3.2.4. Financial Overview
10.3.2.5. SWOT Analysis
10.3.2.6. Strategic overview
10.3.3. GLyPharma Therapeutic, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Business Overview
10.3.3.3. Product Portfolio
10.3.3.4. Financial Overview
10.3.3.5. SWOT Analysis
10.3.3.6. Strategic overview
10.3.4. Merck KGaA
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Business Overview
10.3.4.3. Product Portfolio
10.3.4.4. Financial Overview
10.3.4.5. SWOT Analysis
10.3.4.6. Strategic overview
10.3.5. Naia Pharmaceuticals, Inc.
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Business Overview
10.3.5.3. Product Portfolio
10.3.5.4. Financial Overview
10.3.5.5. SWOT Analysis
10.3.5.6. Strategic overview
10.3.6. Nutrinia Ltd.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Business Overview
10.3.6.3. Product Portfolio
10.3.6.4. Financial Overview
10.3.6.5. SWOT Analysis
10.3.6.6. Strategic overview
10.3.7. OxThera
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Business Overview
10.3.7.3. Product Portfolio
10.3.7.4. Financial Overview
10.3.7.5. SWOT Analysis
10.3.7.6. Strategic overview
10.3.8. Sancilio & Company, Inc.
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Business Overview
10.3.8.3. Product Portfolio
10.3.8.4. Financial Overview
10.3.8.5. SWOT Analysis
10.3.8.6. Strategic overview
10.3.9. Shire plc
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Business Overview
10.3.9.3. Product Portfolio
10.3.9.4. Financial Overview
10.3.9.5. SWOT Analysis
10.3.9.6. Strategic overview
10.3.10. Zealand Pharma A/S
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Business Overview
10.3.10.3. Product Portfolio
10.3.10.4. Financial Overview
10.3.10.5. SWOT Analysis
10.3.10.6. Strategic overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers